The TCs benefit may be due to the development of patients’ skin toxicity and not due to the TC itself However, the effect of the concomitant use of EGFR-TKIs, PPIs, and TCs on the PFS and OS was similar to that of EGFR-TKI therapy alone. Here, EGFR is linked to dermatological toxicity.